Home » Pharmacology » Ion Channels » Ligand-gated Ion Channels » Glutamate (Ionotropic) Receptors » NMDA Receptors » DQP 1105

DQP 1105

Cat. No. 4491

Price and Availability

For DQP 1105 pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 5-(4-Bromophenyl)-3-(1,2-dihydro-6-methyl-2-oxo-4-phenyl-3-quinolinyl)-4,5-dihydro-g-oxo-1H-pyrazole-1-butanoic acid

Biological Activity

Noncompetitive NMDA receptor antagonist; displays over 50-fold selectivity for GluN2D- and GluN2C-containing receptors over GluN2B-, GluK2-, GluA1- and GluN2A-containing receptors (IC₅₀ values are 2.7, 8.5, 121, 153, 198 and 206 μM respectively). Reduces frequency of channel opening.

Technical Data

M.Wt:

558.42

Formula:

C₂₉H₂₄BrN₃O₄

Solubility:

Soluble to 100 mM in DMSO

Purity:

>97 %

Storage:

Store at -20°C

CAS No:

380560-89-4

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Safety Data Sheet: View Safety Data Sheet

References

Acker et al (2011) Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol.Pharmacol. 80 782. PMID: 21807990.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Glutamate (Ionotropic) Receptors

NMDA Receptors

Keywords: DQP 1105, supplier, DQP1105, supplier, NMDAD, NMDAD, Glu2NC, Glu2NC, antagonists, selective, noncompetitive, inhibitors, inhibits

Quick Order

Find multiple products by catalog number

Pain Research Guide

Reserve your free copy

Highlights over 280 products for Pain research. Reserve copy

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

Calcium Imbalance and Neuroprotective Targets

Written by E. Besancon et al

'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.

Neurobiology of Parkinson's Disease

Written by A. Schapira

'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.